Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Tasmar

Executive Summary

Anti-Parkinson's agent Tasmar (tolcapone) is no longer being promoted, Roche says. The company received a letter from FDA's ad division Aug. 2 objecting to the dissemination of introductory promotional materials, including the outdated claim that Tasmar is the "only COMT inhibitor." Roche told FDA that it ceased all promotion of Tasmar in September 2000. The drug was withdrawn in Europe and relabeled in the U.S. in 1998 due to liver toxicity reports
Advertisement

Related Content

FDA, Kaiser Discussing COX-2 Myocardial Infarction Study
FDA, Kaiser Discussing COX-2 Myocardial Infarction Study
Advertisement
UsernamePublicRestriction

Register

PS038384

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel